David Badawi Sells 3,829 Shares of Sight Sciences, Inc. (NASDAQ:SGHT) Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CTO David Badawi sold 3,829 shares of the company’s stock in a transaction on Wednesday, January 8th. The stock was sold at an average price of $3.26, for a total transaction of $12,482.54. Following the completion of the transaction, the chief technology officer now directly owns 1,749,541 shares in the company, valued at approximately $5,703,503.66. The trade was a 0.22 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

David Badawi also recently made the following trade(s):

• On Friday, January 3rd, David Badawi sold 3,111 shares of Sight Sciences stock. The stock was sold at an average price of $3.52, for a total value of $10,950.72.

Sight Sciences Price Performance

SGHT stock opened at $3.25 on Friday. The firm has a market cap of $164.95 million, a P/E ratio of -3.19 and a beta of 2.57. The firm’s fifty day moving average is $3.82 and its 200 day moving average is $5.52. Sight Sciences, Inc. has a 52 week low of $3.16 and a 52 week high of $8.45. The company has a debt-to-equity ratio of 0.36, a quick ratio of 9.74 and a current ratio of 10.18.

Sight Sciences (NASDAQ:SGHT) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.01. Sight Sciences had a negative return on equity of 47.28% and a negative net margin of 63.30%. The firm had revenue of $20.16 million for the quarter, compared to analysts’ expectations of $20.41 million. Research analysts predict that Sight Sciences, Inc. will post -1.01 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. UBS Group started coverage on Sight Sciences in a research report on Friday, December 6th. They set a “buy” rating and a $5.50 price target for the company. Piper Sandler reiterated a “neutral” rating and set a $5.50 target price (down from $6.00) on shares of Sight Sciences in a research report on Friday, November 8th. Lake Street Capital lowered shares of Sight Sciences from a “buy” rating to a “hold” rating and decreased their price target for the stock from $10.00 to $5.00 in a report on Monday, November 4th. Citigroup dropped their price objective on shares of Sight Sciences from $5.80 to $4.60 and set a “neutral” rating for the company in a report on Wednesday, December 11th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Sight Sciences in a research note on Friday, November 8th. Five analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $5.12.

Institutional Trading of Sight Sciences

Hedge funds and other institutional investors have recently bought and sold shares of the stock. SG Americas Securities LLC bought a new position in shares of Sight Sciences in the third quarter worth approximately $75,000. The Manufacturers Life Insurance Company purchased a new stake in Sight Sciences during the 2nd quarter valued at $95,000. GSA Capital Partners LLP bought a new stake in Sight Sciences in the 3rd quarter worth $136,000. American Century Companies Inc. increased its position in shares of Sight Sciences by 31.1% in the second quarter. American Century Companies Inc. now owns 35,948 shares of the company’s stock valued at $240,000 after acquiring an additional 8,527 shares during the period. Finally, Rhumbline Advisers raised its stake in shares of Sight Sciences by 40.1% during the second quarter. Rhumbline Advisers now owns 40,811 shares of the company’s stock valued at $272,000 after acquiring an additional 11,671 shares during the last quarter. Institutional investors own 55.51% of the company’s stock.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.